Table 1. Main clinical data depicted in the text about potential predictive biomarkers in platinum-treated NSCLC patients. In the table the data are summarized according to the methodology used.
| Methodology | Clincal study type | Clinical setting | Biomarker | Results | Reference |
|---|---|---|---|---|---|
| DNA repair capacity in peripheral lymphocytes | Retrospective evaluation | Platinum-treated NSCLC | DNA repair capacity | Trend for improved OS in patients with low DNA repair capacity | (43) |
| Single DNA repair component at protein level | Retrospective evaluation | Adjuvant | ERCC1 | OS benefit from platinum-treatment only in low/negative expressing ps | (44) |
| Retrospective evaluation | Adjuvant | ERCC1; BRCA1 | Improved DFS for SCC with low/negative expression of ERCC1 | (45) | |
| Single DNA repair component at mRNA level | Retrospective evaluation | Advanced disease | ERCC1; RRM1 | Improved OS for low-expressing ps | (18) |
| Retrospective evaluation | Advanced disease | ERCC1 | Improved OS for low-expressing ps | (46) | |
| Retrospective evaluation | Advanced disease (second-line) | ERCC1; BRCA1 | Higher RR, PFS, OS for low-expressing ps | (47) | |
| Retrospective evaluation | Advanced disease | RRM1 | Improved OS for low-expressing ps | (16) | |
| Retrospective evaluation | Advanced disease | RRM1 | Improved OS for low-expressing ps | (17) | |
| Individual patient analysis | Advanced disease | ERCC1; RRM1 | Improved RR and OS in ps treated with customized CT according to ERCC1 and RRM1 | (48) | |
| Phase III trial | Advanced disease | ERCC1 | Improved RR in ps treated with customized CT according to ERCC1 | (49) | |
| Retrospective evaluation | Neoadjuvant | BRCA1 | Improved OS for low-expressing ps | (50) | |
| Phase II | Advanced disease | BRCA1 | Feasibility of customized CT according to BRCA1 mRNA | (51) | |
| Retrospective evaluation | Advanced disease | ERCC1 | Negative | (52) | |
| Retrospective evaluation | Advanced disease | ERCC1; BRCA1 | Improved RR, PFS, OS for ps expressing low ERCC1 | (53) | |
| CTCs evaluation of a single DNA repair component | Retrospective evaluation | Advanced disease | ERCC1 | Improved PFS in ps expressing low ERCC1 | (54) |
| Integrated DNA repair components analysis | Retrospective evaluation | Advanced disease | BRCA1; RAP80 | Trend for Improved PFS and OS for ps expressing low BRCA1 and RAP80 | (51) |
Abbreviations: CTCs, circulating tumor cells; DFS, disease free survival; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression free survival; ps, patients; RR, response rate; SCC, squamous cell carcinoma